E209 - (CME) Harnessing Pharmacogenomic Testing as a Tool in Major Depressive Disorder Treatment

In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-GEN

Learning Objectives: After completing this educational activity, you should be better able to:

• Recognize the role of a patient’s genetics in informing the efficacy and tolerability of antidepressants
• Consider opportunities to use pharmacogenomics as an evidence-based tool that can be employed to inform clinical decision making
• Implement pharmacogenomic testing to optimize patient outcomes, including symptom improvement, medication response, and remission rate

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Credit Types: The following are being offered for this activity:

• Nurse Practitioner: ANCC contact hours
• Pharmacy: ACPE application-based contact hours
• Physician: ACCME AMA PRA Category 1 Credits ™
• Physician Associate: AAPA Category 1 CME credits
• Psychology: APA CE credits
• Social Work: ASWB-ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented.

Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma

Interviewee Jeffrey R. Strawn, MD Professor, Department of Psychiatry and Behavioral Neuroscience and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH Grant/Research: Allergan/AbbVie Consultant/Advisor: Cerevel, Intra-Cellular, Otsuka

Pre-Interview Author Gabriela Alarcón, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.

The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Support: This activity is supported by an unrestricted educational grant from Myriad Genetics.

Released: December 13, 2023      CME/CE credit expires: December 13, 2026